For people living with polycythemia vera, treatment has long meant returning to a clinic to have blood physically removed, sometimes every few weeks, indefinitely. A newly approved weekly injection reduced that requirement for most patients in its pivotal trial.
The Food and Drug Administration approved Mimrylo for polycythemia vera, known generically as rusfertide, for the treatment of erythrocytosis in adults with the disease. It is the first approved treatment for the condition that mimics hepcidin, the hormone that naturally regulates iron in the body.
